Long Term Outcomes of the Transcatheter Pulmonary Valve Melody

Original title: Clinical and Hemodynamic Outcomes Up to 7 Years After Transcatheter Pulmonary Valve Replacement in the US Melody Valve Investigational Device Exemption Trial. Reference: Circulation. 2015 May 5. [Epub ahead of print]. Published studies on transcatheter pulmonary valve replacement with the Melody valve have shown good short term outcomes but there is no information of long term<a href="https://solaci.org/en/2015/05/18/long-term-outcomes-of-the-transcatheter-pulmonary-valve-melody/" title="Read more" >...</a>

DES and programmed surgery: reality or myth

Original title: Drug-Eluting Stents versus Bare Metal Stents Prior to Noncardiac Surgery. Reference: Sripal Bangalore, et al. Catheterization and Cardiovascular Intervention 2015;85:533-41 Drug eluting stents (DES) have proved beneficial compared to bare metal stents (BMS), but the need to program a surgical procedure after a percutaneous coronary intervention (PCI) has limited its use. This study analyzed patients receiving<a href="https://solaci.org/en/2015/05/12/des-and-programmed-surgery-reality-or-myth/" title="Read more" >...</a>

Clinical presentation of restenosis in the three generations of DES

Original title: Clinical Presentation and Outcomes of Coronary In-Stent Restenosis Across 3-Stent Generations. Reference: Marco A. Magalhaes et al. Circ Cardiovasc Interv. 2014;7:00-00. Studies evaluating the clinical presentation of restenosis after implantation of bare metal stent showed that the recurrence of stenosis is not a benign complication as previously thought, with a significant number of patients with restenosis<a href="https://solaci.org/en/2015/04/28/clinical-presentation-of-restenosis-in-the-three-generations-of-des/" title="Read more" >...</a>

Angioplasty using a drug eluting balloon in the superficial femoral artery

Original title: Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease 12-Month Results From the IN.PACT SFA Randomized Trial. Reference: Gunnar Tepe et al. Circulation. 2015;131:495-502. This interesting study randomly selected 331 patients with intermittent claudication or ischemic rest pain due to stenosis of the superficial femoral artery or<a href="https://solaci.org/en/2015/04/27/angioplasty-using-a-drug-eluting-balloon-in-the-superficial-femoral-artery/" title="Read more" >...</a>

FFR to guide treatment of secondary vessel on bifurcations

Original title: Randomized Comparison of FFR-Guided and Angiography-Guided Provisional Stenting of True Coronary Bifurcation Lesions The DKCRUSH-VI (Double Kissing Crush Versus Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions VI) Trial. Reference: Shao-Liang Chen et al. J Am Coll Cardiol Intv. 2015. Online before print. Angiography for guiding the need to implant a stent in the side<a href="https://solaci.org/en/2015/04/22/ffr-to-guide-treatment-of-secondary-vessel-on-bifurcations/" title="Read more" >...</a>

Risks and benefits of extending dual antiplatelet therapy in patients with and without MI

Original title: Benefits and Risks of Extended Duration Dual Antiplatelet Therapy after PCI in Patients With and Without Acute Myocardial Infarction. The DAPT Study. Reference: Robert W. Yeh et al. J Am Coll Cardiol. 2015, online before print. The risks and benefits of prolonged antiplatelet therapy after PCI could be different in patients presenting with AMI compared to<a href="https://solaci.org/en/2015/04/21/risks-and-benefits-of-extending-dual-antiplatelet-therapy-in-patients-with-and-without-mi/" title="Read more" >...</a>

Duration of double antiaggregation therapy in patients with oral anticoagulation

Original title: Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent ImplantationThe ISAR-TRIPLE Trial. Reference: Katrin A. Fiedler et al. J Am Coll Cardiol. 2015;65(16):1619-1629. Patients with oral anticoagulation indication after drug eluting stenting require aspirin and clopidogrel; however, the triple scheme has high bleeding risk and optimal duration is yet to be determined. The<a href="https://solaci.org/en/2015/04/20/duration-of-double-antiaggregation-therapy-in-patients-with-oral-anticoagulation/" title="Read more" >...</a>

Supervised exercise is as important as revascularization in aortoiliac peripheral artery disease

Original title: Supervised Exercise, Stent Revascularization, or Medical Therapy for Claudication Due to Aortoiliac Peripheral Artery DiseaseThe CLEVER Study. Reference: J Am Coll Cardiol. 2015;65(10):999-1009. Percutaneous revascularization has been effective to treat claudication due to aortoiliac peripheral artery disease. However, supervised exercise can also offer benefits in terms of functional class and quality of life, at least in<a href="https://solaci.org/en/2015/04/14/supervised-exercise-is-as-important-as-revascularization-in-aortoiliac-peripheral-artery-disease/" title="Read more" >...</a>

Is the 2nd generation DES an alternative to surgery in multivessel coronary disease?

The benefits of 2nd generation drug-eluting stents (DES) are being compared with Coronary artery bypass graft surgery (CABG), looking to achieve a safe, effective, less invasive and as complete as possible revascularization. As background of SYNTAX, the stent thrombosis (ST) with Taxus, reached 25% of the events in the group of intervention (PCI), so that<a href="https://solaci.org/en/2015/04/07/is-the-2nd-generation-des-an-alternative-to-surgery-in-multivessel-coronary-disease/" title="Read more" >...</a>

Bioresorbable vascular scaffold vs. the best-in-class DES

Original title: Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. Referencia: Puricel S. et al. J Am Coll Cardiol. 2015 Mar 3;65(8):791-801. The everolimus eluting bioresorbable scaffold (BVS) is effective at treating simple lesions in stable patients but it has yet to be assessed against the best-in-class DES. This study compared BVS performance against<a href="https://solaci.org/en/2015/04/01/bioresorbable-vascular-scaffold-vs-the-best-in-class-des/" title="Read more" >...</a>